Blastoid Mantle Cell Lymphoma.
Aggressive mantle cell lymphoma
BTK
Blastoid
Ibrutinib
Mantle cell lymphoma
Pleomorphic
Transformation
Venetoclax
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
entrez:
31
8
2020
pubmed:
31
8
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity. De novo blastoid MCLs have superior outcomes compared with transformed MCL. Compared with classic MCL, extranodal involvement (mainly skin, central nervous system), frequent relapses, and inferior responses to conventional chemoimmunotherapy, BTK inhibitors and venetoclax are frequent in blastoid MCL. KTE-X19 induces excellent response in blastoid MCL. Combinations with novel agents are actively investigated. This article presents a comprehensive review on blastoid MCL in 2020.
Identifiants
pubmed: 32861288
pii: S0889-8588(20)30072-1
doi: 10.1016/j.hoc.2020.06.009
pii:
doi:
Substances chimiques
Bridged Bicyclo Compounds, Heterocyclic
0
Receptors, Chimeric Antigen
0
Sulfonamides
0
brexucabtagene autoleucel
4MD2J2T8SJ
venetoclax
N54AIC43PW
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
941-956Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure P. Jain: none. M. Wang: stock or othe ownership in MoreHealth; honoraria from Pharmacyclics, Janssen, AstraZeneca/Acerta Pharma, Targeted Oncology, and OMI; consultancy or advisory role for Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta Pharma, MoreHealth, Loxo Oncology, Kite, a Gilead Company, and Pulse Biosciences; research funding from Pharmacyclics, Janssen, AstraZeneca/Acerta Pharma, BioInvent, Novartis, Kite, a Gilead Company, Juno, Celgene, Loxo Oncology, and VelosBio; expert testimony for AstraZeneca/Acerta Pharma; and travel support from Janssen, Pharmacyclics, Celgene, Targeted Oncology, and OMI.